for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioMerieux SA

BIOX.PA

Latest Trade

75.15EUR

Change

-0.20(-0.27%)

Volume

22,524

Today's Range

74.80

 - 

75.70

52 Week Range

53.10

 - 

78.85

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
75.35
Open
75.30
Volume
22,524
3M AVG Volume
1.83
Today's High
75.70
Today's Low
74.80
52 Week High
78.85
52 Week Low
53.10
Shares Out (MIL)
118.34
Market Cap (MIL)
8,918.52
Forward P/E
31.75
Dividend (Yield %)
0.46

Next Event

Q3 2019 Biomerieux SA Business Review

Latest Developments

More

Biomerieux H1 Net Attributable Income Up At Eur 141 Mln

BioMerieux Increases Its Holding In Hybiome To 67%

Biomerieux Q1 Consolidated Sales 632 Million Euros

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioMerieux SA

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

Industry

Biotechnology & Drugs

Contact Info

376 chemin de l'Orme

+33.4.78872000

http://www.biomerieux.fr/

Executive Leadership

Alexandre Merieux

Chairman of the Board, Chairman of the Executive Committee, Chief Executive Officer, Non-Independent Director

Guillaume Bouhours

Corporate Vice President, Chief Financial Officer, Member of the Executive Board

Michel Baguenault

Executive Vice-President, Member of the Executive Board, Secretary General, Head of Human Resources, Communications, Legal Affairs and Intellectual Property

Pierre Boulud

Corporate Vice-President, Asia-Pacific Region, Industrial Unit, Investments and Strategic Planning, Member of the Executive Board

Nicolas Cartier

Corporate Vice President Industrial Applications unit, Member of the Executive Board

Key Stats

3.27 mean rating - 15 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

2.1K

2017

2.3K

2018

2.4K

2019(E)

2.6K
EPS (EUR)

2016

1.513

2017

2.020

2018

2.180

2019(E)

2.374
Price To Earnings (TTM)
33.95
Price To Sales (TTM)
3.53
Price To Book (MRQ)
4.32
Price To Cash Flow (TTM)
19.81
Total Debt To Equity (MRQ)
32.41
LT Debt To Equity (MRQ)
25.19
Return on Investment (TTM)
9.89
Return on Equity (TTM)
7.71

Latest News

Latest News

Turkey's BIM 2018 net profit jumps 45 percent to 1.25 bln lira

Turkish discount retailer BIM posted a net profit of 1.25 billion lira ($230 million) in 2018, up 45 percent from a year earlier, it said late on Wednesday.

BRIEF-Biomerieux Q1 Sales Up 3.4 Percent 587 Million Euros

* NET DEBT AMOUNTED TO EUR 84 MILLION AT MARCH 31, 2018, VERSUS EUR 156 MILLION AT DECEMBER 31, 2017

BRIEF-Biomerieux Acquires Astute Medical Inc. For About $90 Mln In Cash

* ANNOUNCED ON WEDNESDAY, ACQUISITION OF ASTUTE MEDICAL INC FOR ABOUT $90 MLN IN CASH

BRIEF-Biomerieux FY Sales Up At 2.29 Billion Euros

* FY OPERATING INCOME EUR 315 MILLION VERSUS EUR 282 MILLION YEAR AGO

BRIEF-Biomerieux FY ‍Sales Rise 10.2 Pct To EUR 2,288 Million

* SALES MOMENTUM IN 2017 WITH 10.2% GROWTH IN SALES TO EUR 2,288 MILLION IN SALES

BRIEF-Biomerieux Appoints Alexandre Merieux As CEO And Chairman

* ALEXANDRE MÉRIEUX APPOINTED CHAIRMAN AND CEO OF BIOMÉRIEUX Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Veneto Banca seals deal with Attestor over BIM stake sale

* signed an agreement with Trinity Investments Designated Activity Company, an investment company managed by Attestor Capital, over sale of its stake in BIM

BRIEF-Biomerieux Q3 sales up at 1.67 billion euros

* Q3 SALES EUR 1.67 BILLION VERSUS EUR 1.51 BILLION YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biomerieux H1 operating income rises to 163 million euros

* IS NOW TARGETING ORGANIC SALES GROWTH FOR FULL YEAR OF BETWEEN 9 PCT AND 10 PCT

BRIEF-Bim Q2 net profit rises 50% to 216.4 mln lira, revises 2017 revenue growth outlook to 20-23%

* REPORTED ON MONDAY Q2 REVENUE OF 6.21 BILLION LIRA VERSUS 4.91 BILLION LIRA YEAR AGO

BRIEF-Biomérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

* BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR EXPANDED PATHOGEN IDENTIFICATION CAPABILITY ON VITEK® MS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Sysmex and Biomérieux agreed to dissolve JV Sysmex Biomérieux co., ltd.

* SYSMEX AND BIOMÉRIEUX AGREED TO DISSOLVE THE JOINT VENTURE SYSMEX BIOMÉRIEUX CO., LTD.

BRIEF-Biomerieux H1 sales up at 1,134 million euros

* SALES UP 11.3% OVER FIRST HALF AT CONSTANT EXCHANGE RATES AND SCOPE OF CONSOLIDATION

Veneto Banca says has started process to sell stake in BIM

Veneto Banca, one of two troubled regional lenders Italy is winding down, said on Thursday it had started the process to sell its controlling stake in private banking group BIM <BIM.MI>.

Italy's BIM head confident the unit can be sold fast after Veneto Banca liquidation

The head of Italy's BIM <BIM.MI> said on Monday he was confident the private banking group would be sold on the market quickly following the decision to liquidate its main shareholder Veneto Banca.

BRIEF-Bim to establish a food supply and packaging company with 5.0 mln lira capital

* TO ESTABLISH A %100 OWNED UNIT WITH 5.0 MILLION LIRA CAPITAL IN ORDER TO PROVIDE THE SUPPLY AND PACKAGING OF VARIOUS FOOD ITEMS ESPECIALLY RICE AND PULSE PRODUCTS SOLD IN THE COMPANY RETAIL STORES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Biomerieux receives FDA clearance for BioFire’s FilmArray Respiratory Panel 2 (RP2)

* BIOMÉRIEUX RECEIVES FDA CLEARANCE FOR BIOFIRE’S FILMARRAY RESPIRATORY PANEL 2 (RP2)

BRIEF-Chairman Mustafa Latif Topbas transfers 14.78 pct stake in BIM to Merkez Bereket Gida-KAP

* CHAIRMAN MUSTAFA LATIF TOPBAS TRANSFERS HIS 14.78 PCT DIRECT STAKE IN BIM TO MERKEZ BEREKET GIDA AT 61.0 LIRA PER SHARE-KAP

BRIEF-Biomerieux Q1 Consolidated sales rise to 568 million euros

* Consolidated sales rose to 568 million euros ($609.18 million) for the first three months of 2017, up from 489 million euros in the same period one year earlier Source text: http://bit.ly/2piknxJ Further company coverage: ($1 = 0.9324 euros) (Gdynia Newsroom:)

BRIEF-Biomerieux receives FDA 510(k) clearance for BacT/ALERT VIRTUO fully automated blood culture system

* Biomerieux receives FDA 510(k) clearance for its BacT/ALERT VIRTUO fully automated blood culture system Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up